Biotin biosynthetic genes

Details Biotin biosynthetic genes Biotin biosynthetic genes

2001-12-27

2004-04-20

Achutamurthy, Ponnathapu (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C435S041000, C435S183000, C435S252300, C435S252330, C435S320100, C536S023100, C536S023200

Reexamination Certificate

active

06723544

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to the production process of biotin by fermentation using a genetically engineered organism.
Biotin is one of the essential vitamins for nutrition of animals, plants, and microorganisms, and very important as medicine or food additives.
Biotin biosynthesis of
Escherichia coli
has been studied well, and it has been clarified that biotin is synthesized from pimelyl CoA via 7 keto-8-amino pelargonic acid (KAPA), 7,8-diamino pelargonic acid (DAPA) and desthiobiotin (DTB) [
Escherichia coli
and
Salmonella typhimurium,
Cellular and Molecular Biology, 544, (1987)]. The analysis of genetic information involved in the biosynthesis of biotin has been advanced on
Escherichia coli
[J. Biol. Chem., 263, 19577, (1988)] and
Bacillus sphaericus
(U.S. Pat. No. 5,096,823). At least four enzymes are known to be involved in this biosynthetic pathway. These four enzymes are encoded by the bioA, bioB, bioD and bioF genes. The bioF gene codes for KAPA synthetase which catalyzes the conversion of pimelyl CoA to KAPA. The bioA gene codes for DAPA aminotransferase which converts KAPA to DAPA. The bioD gene codes for DTB synthetase which converts DAPA to DTB. The bioB gene codes for biotin synthase which converts DTB to biotin. It has been also reported that the bioC and bioH genes are involved in the synthesis of pimelyl CoA in
Escherichia coli.
There are many studies on fermentative production of biotin.
Escherichia coli
(Japanese Patent Kokai No. 149091/1986 and Japanese Patent Kokai No. 155081/1987),
Bacillus sphaericus
(Japanese Patent Kokai No. 180174/1991),
Serratia marcescens
(Japanese Patent Kokai No. 27980/1990) and
Brevibacterium flavum
(Japanese Patent Kokai No. 240489/1991) have been used. But these processes have not yet been suitable for use in an industrial production process because of a low productivity. Moreover, large amounts of DTB, a biotin precursor, accumulates in the fermentation of these bacteria. Therefore, it has been assumed that the last step of the biotin biosynthetic pathway, from DTB to biotin, is a rate limiting step.
On the other hand, it was found that a bacterial strain belonging to the genus Kurthia produces DTB and small amounts of biotin. Also mutants which produce much larger amounts of biotin were derived from wild type strains of the genus Kurthia by selection for resistance to biotin antimetabolites acidomycin (ACM), 5-(2-thienyl)-valeric acid (TVA) and alpha-methyl desthiobiotin (MeDTB). However, in view of the still low biotin titers it is desirable to apply genetic engineering to improve the biotin productivity of such mutants.
SUMMARY OF THE INVENTION
The present invention relates therefore to the chromosomal DNA fragments carrying the genes involved in the biotin biosynthesis of Kurthia sp. The isolated chromosomal DNA fragments carry 8 genes, the bioA, bioB, bioC, bioD, bioF, bioFII, bioH and bioHII genes, and transcriptional regulatory sequences. The bioFII gene codes for an isozyme of the bioF gene product. The bioHII gene codes for an isozyme of the bioH gene product.
The present invention further relates to Kurthia sp. strains in which at least one gene involved in biotin biosynthesis is amplified, and also to the production process of biotin by this genetically engineered Kurthia sp. strain.
Although the DNA fragment mentioned above may be of various origins, it is preferable to use the strains belonging to the genus Kurthia. Specific examples of such strains include, for example, Kurthia sp. 538-6 (DSM No. 9454) and its mutant strains by selection for resistance to biotin antimetabolites such as Kurthia sp. 538-KA26 (DSM No. 10609).


REFERENCES:
patent: 5096823 (1992-03-01), Gloeckler et al.
patent: 5922581 (1999-07-01), Hoshino et al.
patent: 6277609 (2001-08-01), Eddy
patent: 0 375 525 (1990-06-01), None
patent: 0 635 572 (1995-01-01), None
patent: 0 747 483 (1996-12-01), None
patent: 0 799 895 (1997-10-01), None
patent: WO 87/01391 (1987-03-01), None
patent: WO 94/08023 (1994-04-01), None
Gloeckler et al. Accession A02567. Feb. 28, 1994.*
Attwood et al. Which craft is best in bioinformatics? Comput. Chem. 2001, vol. 25(4), pp. 329-339.*
Ponting, C.P. Issues in predicting protein function from sequence. Brief. Bioinform. Mar. 2001, vol. 2(1), PP. 19-29.*
Derwent Abstract No. 86-216622 of Japanese Patent Kokai 149091/1986.
Derwent Abstract No. 87-231579 of Japanese Patent Kokai 155081/1987.
Derwent Abstract No. 90-226023 of Japanese Patent Kokai 180174/1991.
Derwent Abstract No. 90-072971 of Japanese Patent Kokai 27980/1990.
Derwent Abstract No. 91-358298 of Japanese Patent Kokai 240489/1991.
Derwent Abstract of EP 375 525.
Cleary, et al., “Deletion and Complementation Analysis of the Biotin Gene Cluster ofEscherichia coli,”J. Bacterial., 112:830-839 (1972).
Barker, et al., “Use of bio-lac Fusion Strains to Study Regulation of Biotin Biosynthesis inEscherichia coli,”J. Bacterial, 143:789-800 (1980).
Tanaka, et al., “Site-Specific In vitro Binding of Plasmit pUB110 toBacillus subtilisMembrane Factor,”J. Bacteriol., 154:1184-1194 (1983).
Otsuka, et al., “TheEscherichia coliBiotin Biosynthetic Enzyme Sequences Predicted from the Nucleotide Sequence of the bio Operon,”J. Biol. Chem., 263:19577-19585 (1988).
Smith, “In vitro Mutagenesis,”Ann. Rev. Genet, 19:423-462 (1985).
Haima, et al., “The Effect of Restriction on Shotgun Cloning and Plasmid Stability inBacillus subtilisMarburg,”Mol. Gen. Genet, 209:335-342 (1987).
Maniatis, et al., “Transformation ofEscherichia coliby Plasmid DNA,”Molecular Cloning, Cold Spring Harbor Laboratory Press, New York, pp. 252-253 (1982).

Affiliated with

Also associated with

Rating

Biotin biosynthetic genes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biotin biosynthetic genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biotin biosynthetic genes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3198639